Drowning in EU regulations? Five tips for surviving the deluge of new rules

As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Emotional Perception: What next for patent holders?

3 March 2026 After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.

Europe

Emotional Perception exclusive: ‘We are now very much open for business’

16 February 2026 Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.

Europe

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

12 February 2026 The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.

More features

Mylan withdraws defence claims against Novo in Wegovy dispute

INTA: ‘New normal’ for in-house counsel as budgets fall

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

Drowning in EU regulations? Five tips for surviving the deluge of new rules

More on this story

Editor's picks

Editor's picks

More features